ISSUE: Over the last decade, the understanding of disease biology and care, in particular in the oncology field, has greatly increased. It has enabled the development of targeted therapies as well as cancer immunotherapies that stimulate the human body´s immune system to fight cancer. With this increased scientific understanding, researchers discover over time that the same molecular aberrations may not only occur in one, but in several cancer indications, thus suggesting clinical benefits of therapies in multiple indications with the same aberration. This suggests that combining multiple targeted therapies often also in combination with cancer immunotherapies, either simultaneously or sequentially, would provide clinical benefits to patients in fighting cancer. In the current environment, increased use of medicines in multiple indications and combinations poses an access challenge. Current pricing and reimbursement systems in Europe usually allow for only one price for one molecule across all its indications. In case of combinations in most healthcare systems the price reflects the sum of the monotherapy price regardless of the clinical value delivered. Moreover when products from multiple manufacturers are combined, current pricing and reimbursement systems hamper the ability to negotiate on the basis of the clinical profile of the combination. As a consequence, patient access to innovative combination therapies may be delayed or not granted at all. OVERVIEW: Introduction by moderator: Patient view and needs with regards to the scientific and clinical evolution and the resulting evolving treatment paradigm. Presentation 1: Swiss experiences of methods that allow combination pricing Switzerland Presentation 2 (Jens Grüger): Industry proposals for sustainable access for cross-company combinations Presentation 3 (tbc): Building on previous presentations, reflections from a country currently reflecting on solutions to implement